胆汁酸代谢异常在非酒精性脂肪性肝病发展中的作用

张学敏; 田云粉

doi:10.12259/j.issn.2095-610X.S20231125

胆汁酸代谢异常在非酒精性脂肪性肝病发展中的作用

doi: 10.12259/j.issn.2095-610X.S20231125

张学敏,
田云粉^,

昆明理工大学附属医院/云南省第一人民医院儿科，云南昆明　650032

基金项目: 国家自然科学基金资助项目（81760110）

详细信息

作者简介:
张学敏（1998～），女，山东济宁人，在读硕士研究生，主要从事小儿消化临床及研究工作

通讯作者:
田云粉，E-mail：136506595@qq.com

中图分类号: R725.7
计量
- 文章访问数: 1000
- HTML全文浏览量: 803
- PDF下载量: 25
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-12
- 网络出版日期: 2023-11-04
- 刊出日期: 2023-11-30

Role of Abnormal Bile Acid Metabolism in the Development of Non-alcoholic Fatty Liver Disease

Xuemin ZHANG,
Yunfen TIAN^,

Dept. of Pediatrics，The Affiliated Hospital of Kunming University of Science and Technology/Dept. of Pediatrics，The 1st People’s Hospital of Yunnan Province，Kunming Yunnan 650032，China

摘要

摘要: 非酒精性脂肪性肝病逐渐成为全球儿童发病率最高的慢性肝病之一，肠肝循环中扮演重要角色的胆汁酸在其发病机制中的作用日渐突出。近年来，研究发现胆汁酸是法尼醇X受体和G蛋白偶联受体5的信号分子，二者作为胆汁酸受体调控全身代谢。胆汁酸代谢失衡与NAFLD严重程度密切相关。对胆汁酸及其受体在NAFLD进展中的作用进行综述，以期为NAFLD无创诊断及治疗提供新的靶点。
- 胆汁酸代谢 /
- 非酒精性脂肪性肝病 /
- 法尼醇X受体 /
- G蛋白偶联受体5
Abstract: Non-alcoholic fatty liver disease is emerging as one of the most prevalent chronic liver diseases in children worldwide, and bile acids, which play an important role in the enterohepatic circulation are becoming increasingly prominent in its pathogenesis. In recent years, it has been found that bile acids are^[1] signaling molecules for farnesol X receptor and G protein-coupled receptor 5, both of which act as bile acid receptors to regulate systemic metabolism. The imbalance of bile acid metabolism is closely related to the severity of NAFLD. This article reviews the role of bile acids and their receptors in the progression of NAFLD with the aim of providing new targets for the noninvasive diagnosis and treatment of NAFLD.
- Bile acids metabolism /
- Non-alcoholic fatty liver disease, NAFLD /
- Farnesol X receptor /
- G protein coupled receptor 5

HTML全文

参考文献(44)

[1]	Younossi Z M,Koenig A B,Abdelatif D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J]. Hepatology,2016,64(1):73-84. doi: 10.1002/hep.28431
[2]	Li J,Zou B,Yeo Y H,et al. Prevalence,incidence,and outcome of non-alcoholic fatty liver disease in Asia,1999-2019: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2019,4(5):389-398. doi: 10.1016/S2468-1253(19)30039-1
[3]	Machado M V,Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know[J]. World J Gastroenterol,2014,20(36):12956-12980. doi: 10.3748/wjg.v20.i36.12956
[4]	Chávez-Talavera O,Tailleux A,Lefebvre P,et al. Bile acid control of metabolism and inflammation in obesity,type2 diabetes,dyslipidemia,and nonalcoholic fatty liver disease[J]. Gastroenterology,2017,152(7):1679-1694. doi: 10.1053/j.gastro.2017.01.055
[5]	Bechmann L P,Kocabayoglu P,Sowa J P,et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis[J]. Hepatology,2013,57(4):1394-1406.
[6]	Puri P,Daita K,Joyce A,et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids[J]. Hepatology,2018,67(2):534-548. doi: 10.1002/hep.29359
[7]	Chow M D,Lee Y H,Guo G L. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Mol Aspects Med,2017,56(4):34-44.
[8]	Xue R,Su L,Lai S,et al. Bile acid receptors and the gut-liver axis in nonalcoholic fatty liver disease[J]. Cells,2021,10(11):2806. doi: 10.3390/cells10112806
[9]	Yang Z X,Shen W,Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease[J]. Hepatol Int,2010,4(4):741-748. doi: 10.1007/s12072-010-9202-6
[10]	Jiao N,Baker S S,Chapa-Rodriguez A,et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD[J]. Gut,2018,67(10):1881-1891. doi: 10.1136/gutjnl-2017-314307
[11]	Arab J P,Karpen S J,Dawson P A,et al. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives[J]. Hepatology,2017,65(1):350-362. doi: 10.1002/hep.28709
[12]	Sinal C J,Tohkin M,Miyata M,et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis[J]. Cell,2000,102(6):731-744. doi: 10.1016/S0092-8674(00)00062-3
[13]	Manchekar M,Kapil R,Sun Z,et al. Relationship between amphipathic β Structures in the β1domain of apolipoprotein B and the properties of the secreted lipoprotein particles in McA-RH7777 cells[J]. Biochemistry,2017,56(31):4084-4094. doi: 10.1021/acs.biochem.6b01174
[14]	Chiang J Y. Bile acid metabolism and signaling[J]. Compr Physiol,2013,3(3):1191-1212.
[15]	Deng W,Fan W,Tang T,et al. Farnesoid X receptor deficiency induces hepatic lipid and glucose metabolism disorder via regulation of pyruvate dehydrogenase kinase 4[J]. Oxid Med Cell Longev,2022,2022:3589525.
[16]	Herzig S,Long F,Jhala U S,et al. CREB regulates hepatic gluconeogenesisthrough the coactivator PGC-1[J]. Nature,2001,413(6852):179-183. doi: 10.1038/35093131
[17]	Carino A,Cipriani S,Marchianò S,et al. Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice[J]. Sci Rep,2017,7(1):13689. doi: 10.1038/s41598-017-13102-y
[18]	Velazquez-Villegas L A,Perino A,Lemos V,et al. TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue[J]. Nat Commun,2018,9(1):245. doi: 10.1038/s41467-017-02068-0
[19]	Thomas C,Gioiello A,Noriega L,et al. TGR5-mediated bile acid sensing controls glucose homeostasis[J]. Cell Metab,2009,10(3):167-177. doi: 10.1016/j.cmet.2009.08.001
[20]	Fang S,Suh J M,Reilly S M,et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance[J]. Nat Med,2015,21(2):159-165. doi: 10.1038/nm.3760
[21]	Seok S,Sun H,Kim Y C,et al. Defective FXR-SHP regulation in obesity aberrantly increases miR-802 expression,promoting insulin resistance and fatty liver[J]. Diabetes,2021,70(3):733-744. doi: 10.2337/db20-0856
[22]	Ding L,Yang L,Wang Z,et al. Bile acid nuclear receptor FXR and digestive system diseases[J]. Acta Pharm Sin B,2015,5(2):135-144. doi: 10.1016/j.apsb.2015.01.004
[23]	Goldspink D A,Lu V B,Billing L J,et al. Mechanistic insights into the detection of free fatty and bile acids by ileal glucagon-like peptide-1 secreting cells[J]. Mol Metab,2018,7:90-101. doi: 10.1016/j.molmet.2017.11.005
[24]	Drucker D J. The biology of incretin hormones[J]. Cell Metab,2006,3(3):153-165. doi: 10.1016/j.cmet.2006.01.004
[25]	Katsuma S,Hirasawa A,Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1[J]. Biochem Biophys Res Commun,2005,329(1):386-390. doi: 10.1016/j.bbrc.2005.01.139
[26]	Holter M M,Chirikjian M K,Briere D A,et al. Compound 18 improves glucose tolerance in a hepatocyte TGR5-dependent manner in mice[J]. Nutrients,2020,12(7):2124. doi: 10.3390/nu12072124
[27]	Lefebvre P,Cariou B,Lien F,et al. Role of bile acids and bile acid receptors in metabolic regulation[J]. Physiol Rev,2009,89(1):147-191. doi: 10.1152/physrev.00010.2008
[28]	Fiorucci S,Di Giorgio C,Distrutti E. Obeticholic acid: An update of its pharmacological activities in liver disorders[J]. Handb Exp Pharmacol,2019,256:283-295.
[29]	Briand F,Brousseau E,Quinsat M,et al. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the diet-induced NASH (DIN) hamster model[J]. Eur J Pharmacol,2018,818:449-456. doi: 10.1016/j.ejphar.2017.11.021
[30]	Yu Y,Liu Y,An W,et al. STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis[J]. J Clin Invest,2019,129(2):546-555.
[31]	Devkota S,Wang Y,Musch M W,et al. Dietary-fat-induced taurocholic acid promotespathobiont expansion and colitis in Il10-/- mice[J]. Nature,2012,487(7405):104-108. doi: 10.1038/nature11225
[32]	Jones B V,Begley M,Hill C,et al. Functional and comparative metagenomic analysisof bile salt hydrolase activity in the human gut microbiome[J]. Proc Natl Acad Sci US A,2008,105(36):13580-13585. doi: 10.1073/pnas.0804437105
[33]	Sayin S I,Wahlström A,Felin J,et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid,a naturally occurring FXR antagonist[J]. Cell Metab,2013,17(2):225-235. doi: 10.1016/j.cmet.2013.01.003
[34]	Ridaura V K,Faith J J,Rey F E,et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice[J]. Science,2013,341(6150):1241214. doi: 10.1126/science.1241214
[35]	Parséus A,Sommer N,Sommer F,et al. Microbiota-induced obesity requires farnesoid X receptor[J]. Gut,2017,66(3):429-437. doi: 10.1136/gutjnl-2015-310283
[36]	Jiang C,Xie C,Li F,et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease[J]. J Clin Invest,2015,125(1):386-402. doi: 10.1172/JCI76738
[37]	Selwyn F P,Csanaky I L,Zhang Y,et al. Importance of large intestine in regulating bile acids and glucagon-like peptide-1 in germ-free mice[J]. Drug Metab Dispos,2015,43(10):1544-1556. doi: 10.1124/dmd.115.065276
[38]	Sutti S,Bruzzì S,Albano E. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: A 2015 update[J]. Expert Rev Gastroenterol Hepatol,2016,10(2):243-253. doi: 10.1586/17474124.2016.1111758
[39]	Biagioli M,Carino A. Signaling from intestine to the host: How bile acids regulate intestinal and liver immunity[J]. Handb Exp Pharmacol,2019,256:95-108.
[40]	Gai Z,Gui T,Alecu I,et al. Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease[J]. Liver Int,2020,40(4):844-859. doi: 10.1111/liv.14340
[41]	Guo C,Xie S,Chi Z,et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome[J]. Immunity,2016,45(4):802-816. doi: 10.1016/j.immuni.2016.09.008
[42]	Shi Y,Su W,Zhang L,et al. TGR5 regulates macrophage inflammation in nonalcoholic steatohepatitis by modulating NLRP3 inflammasome activation[J]. Front Immunol,2021,11:609060. doi: 10.3389/fimmu.2020.609060
[43]	Lallukka S,Sädevirta S,Kallio M T,et al. Predictors of liver fat and stiffness in nonalcoholic fatty liver disease (NAFLD) - an 11-year prospective study[J]. Sci Rep,2017,7(1):14561. doi: 10.1038/s41598-017-14706-0
[44]	Eslam M,Mangia A,Berg T,et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes[J]. Hepatology,2016,64(1):34-46. doi: 10.1002/hep.28475

相关文章(20)

[1]	陈杭, 崔琦, 黄敏杉, 刘建军, 马岚青. miRNA在非酒精性脂肪性肝病中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240101
[2]	李媛媛, 宋亚贤, 徐玉善, 曾晓甫, 袁惠, 徐兆, 江艳. 肠道菌群代谢物TMAO与非酒精性脂肪性肝病的关系, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240210
[3]	李露, 田云粉. 肠道菌群与儿童非酒精性脂肪性肝病的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230708
[4]	杨永锐, 王丽媛, 李海雯, 赵智蓉, 普瑞, 吴贵帅, 李树德. 灯盏乙素抑制NOX的表达改善非酒精性脂肪性肝病肝脏纤维化的研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220721
[5]	李生浩, 丁洁, 王晴晴, 刘思奇, 华丽娟, 段劲宇, 柏保利, 杜安瑞, 常国楫, 李俊义. 慢性乙型病毒性肝炎合并NAFLD患者发生中重度肝损伤的影响因素, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210712
[6]	徐永芳, 吴娜, 胡月新, 赵永美, 郑绍鼎, 危玲, 郑思佳, 刘建军. GW7647对大鼠非酒精性脂肪性肝病（NAFLD）的治疗作用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210804
[7]	梁蔚蔚, 李晓波, 李燕, 刘华, 武俊紫. 艾塞那肽对NAFLD大鼠SREBP1、ACCα及SCD1表达的影响, 昆明医科大学学报.
[8]	张丹, 吕俊衍, 邓溢, 周波, 罗粟风, 王金香, 文玉, 应昀晏, 文代艳, 马岚青. 三种不同饮食干预建立非酒精性脂肪肝模型, 昆明医科大学学报.
[9]	王礴, 夏咸松, 李进涛, 段小花. 细胞色素P450 2E1在甘草甜素治疗非酒精性脂肪肝病中的作用, 昆明医科大学学报.
[10]	薛平燕, 江艳, 徐玉善, 袁惠, 李璇, 宋亚贤, 刘华. 肠道菌群结构在非酒精性脂肪性肝病患者中的改变, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20201120
[11]	陈本超, 李恒, 刘超, 王书廷, 李高峰. G蛋白偶联受体激酶5与非小细胞肺癌的临床相关性, 昆明医科大学学报.
[12]	朱为梅, 华鹏, 罗宇超, 杨红玲, 李亚山, 赵红宇. 低铅染毒抑制非酒精性脂肪性肝病大鼠脂肪酸分解加重其肝脏损伤, 昆明医科大学学报.
[13]	崔坤华, 李琪. 维生素D受体TaqI基因多态性与儿童肾病综合征骨代谢的相关性, 昆明医科大学学报.
[14]	向茜, 李万碧, 张弦, 刘华, 王玉明, 杨才, 白云霞. 维生素D受体基因ApaⅠ、BsmⅠ位点单核苷酸多态性与2型糖尿病肾病的相关性, 昆明医科大学学报.
[15]	向茜. 维生素D受体基因FokI位点单核苷酸多态性与糖尿病肾病的相关性, 昆明医科大学学报.
[16]	田薇. 利拉鲁肽调节脂肪酸的β-氧化改善非酒精性脂肪肝病大鼠症状, 昆明医科大学学报.
[17]	江艳. 非酒精性脂肪性肝患者的代谢紊乱分析, 昆明医科大学学报.
[18]	张媛. 2型糖尿病合并非酒精性脂肪肝病患者Chemerin与氧化应激变化及临床意义, 昆明医科大学学报.
[19]	王慧明. P2X4受体在大鼠脊髓小胶质细胞中的表达, 昆明医科大学学报.
[20]	和海玉. 非酒精性脂肪肝大鼠胃窦Cajal间质细胞的研究, 昆明医科大学学报.